These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 23868008)

  • 1. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a γ-secretase inhibitor, in a preclinical colorectal explant model.
    Arcaroli JJ; Quackenbush KS; Purkey A; Powell RW; Pitts TM; Bagby S; Tan AC; Cross B; McPhillips K; Song EK; Tai WM; Winn RA; Bikkavilli K; Vanscoyk M; Eckhardt SG; Messersmith WA
    Br J Cancer; 2013 Aug; 109(3):667-75. PubMed ID: 23868008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P; Walls M; Qiu M; Ding R; Denlinger RH; Wong A; Tsaparikos K; Jani JP; Hosea N; Sands M; Randolph S; Smeal T
    Mol Cancer Ther; 2010 Jun; 9(6):1618-28. PubMed ID: 20530712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
    Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
    Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer.
    Arcaroli JJ; Powell RW; Varella-Garcia M; McManus M; Tan AC; Quackenbush KS; Pitts TM; Gao D; Spreafico A; Dasari A; Touban BM; Messersmith WA
    Mol Oncol; 2012 Jun; 6(3):370-81. PubMed ID: 22521243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC; Pavlicek A; Zhang Q; Lira ME; Painter CL; Yan Z; Zheng X; Lee NV; Ozeck M; Qiu M; Zong Q; Lappin PB; Wong A; Rejto PA; Smeal T; Christensen JG
    Clin Cancer Res; 2012 Sep; 18(18):5008-19. PubMed ID: 22806875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K; Zhang Q; Li D; Ching K; Zhang C; Zheng X; Ozeck M; Shi S; Li X; Wang H; Rejto P; Christensen J; Olson P
    Clin Cancer Res; 2015 Mar; 21(6):1487-96. PubMed ID: 25564152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D; Dai J; Keller JM; Mizokami A; Xia S; Keller ET
    Clin Cancer Res; 2015 Oct; 21(20):4619-29. PubMed ID: 26202948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamics and pharmacokinetics of the gamma-secretase inhibitor PF-3084014.
    Lanz TA; Wood KM; Richter KE; Nolan CE; Becker SL; Pozdnyakov N; Martin BA; Du P; Oborski CE; Wood DE; Brown TM; Finley JE; Sokolowski SA; Hicks CD; Coffman KJ; Geoghegan KF; Brodney MA; Liston D; Tate B
    J Pharmacol Exp Ther; 2010 Jul; 334(1):269-77. PubMed ID: 20363853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.
    Shang H; Braggio D; Lee YJ; Al Sannaa GA; Creighton CJ; Bolshakov S; Lazar AJ; Lev D; Pollock RE
    Cancer; 2015 Nov; 121(22):4088-96. PubMed ID: 26349011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial testing (stage 1) of the notch inhibitor PF-03084014, by the pediatric preclinical testing program.
    Carol H; Maris JM; Kang MH; Reynolds CP; Kolb EA; Gorlick R; Keir ST; Wu J; Kurmasheva RT; Houghton PJ; Smith MA; Lock RB; Lyalin D
    Pediatr Blood Cancer; 2014 Aug; 61(8):1493-6. PubMed ID: 24664981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel ent-kaurane diterpenoid executes antitumor function in colorectal cancer cells by inhibiting Wnt/β-catenin signaling.
    Ye Q; Yao G; Zhang M; Guo G; Hu Y; Jiang J; Cheng L; Shi J; Li H; Zhang Y; Liu H
    Carcinogenesis; 2015 Mar; 36(3):318-26. PubMed ID: 25600769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells.
    López-Guerra M; Xargay-Torrent S; Rosich L; Montraveta A; Roldán J; Matas-Céspedes A; Villamor N; Aymerich M; López-Otín C; Pérez-Galán P; Roué G; Campo E; Colomer D
    Leukemia; 2015 Jan; 29(1):96-106. PubMed ID: 24781018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atonal homolog 1 is required for growth and differentiation effects of notch/gamma-secretase inhibitors on normal and cancerous intestinal epithelial cells.
    Kazanjian A; Noah T; Brown D; Burkart J; Shroyer NF
    Gastroenterology; 2010 Sep; 139(3):918-28, 928.e1-6. PubMed ID: 20621629
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB; Castillo-Martin M; Hadler M; Ambesi-Impiobato A; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Jakubczak J; Randolph S; Cordon-Cardo C; Ferrando AA
    Mol Cancer Ther; 2012 Jul; 11(7):1565-75. PubMed ID: 22504949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch.
    Floyd DH; Kefas B; Seleverstov O; Mykhaylyk O; Dominguez C; Comeau L; Plank C; Purow B
    Neuro Oncol; 2012 Oct; 14(10):1215-26. PubMed ID: 22962413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers.
    Konishi J; Kawaguchi KS; Vo H; Haruki N; Gonzalez A; Carbone DP; Dang TP
    Cancer Res; 2007 Sep; 67(17):8051-7. PubMed ID: 17804716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance.
    Quackenbush KS; Bagby S; Tai WM; Messersmith WA; Schreiber A; Greene J; Kim J; Wang G; Purkey A; Pitts TM; Nguyen A; Gao D; Blatchford P; Capasso A; Schuller AG; Eckhardt SG; Arcaroli JJ
    Oncotarget; 2016 May; 7(19):28273-85. PubMed ID: 27070088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of Notch and Wnt signaling for chemoresistance of colorectal cancer cells HCT116.
    Kukcinaviciute E; Jonusiene V; Sasnauskiene A; Dabkeviciene D; Eidenaite E; Laurinavicius A
    J Cell Biochem; 2018 Jul; 119(7):5913-5920. PubMed ID: 29637602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.